esperion.com - ESPR Revenue Dynamics YoY (Last Twelve Months)

Brandmark of Esperion Therapeutics (ESPR)

Esperion Therapeutics (ESPR) employs an asset-light strategy, concentrating its R&D in the US while outsourcing the production of Nexletol to third-party contractors. This chart of year-over-year revenue growth over the last 12 months helps filter out market noise from actual business expansion. Its status as a unique alternative to statins provides the company with pricing power, although insurance rebate requirements constrain margins. 60.70 captures the magnitude of this parameter.

Esperion Therapeutics, Inc. - ESPR Sales Growth YoY (TTM) (period 02/11/2024 - 07/25/2026)

Summary analytical data breakdowns for Esperion (ESPR)

- share price and expert price forecast:
Summary company analytics:ESPR (Esperion Corp)
Manufactured product of esperion.com

To minimize investment risks, it is necessary to separate organic revenue growth from one-off factors by analyzing growth rates over a rolling year. The comparative year-over-year sales dynamics for the rolling period measure the percentage change in TTM revenue, allowing for an assessment of how effectively the Esperion (ESPR) cholesterol-fighting ecosystem is capturing the market for therapy for statin-intolerant patients.